



ALN-RSV01

GEMINI Space Program:

A successful human spaceflight launched by NASA that demonstrated many firsts in the history of manned space programs. The GEMINI program holds an important place in man's progress into the frontier of space.

GEMINI RNAi Therapeutic Program:

A successful Phase II clinical study conducted by Alnylam demonstrating the first human proof of concept for an RNAi therapeutic.

In early 2008, Alnylam announced positive results from its GEMINI Phase II experimental infection study with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection. With this accomplishment, we believe we have demonstrated the first-ever human proof of concept for an RNAi therapeutic. The achievements demonstrated by the new data, which showed statistically significant anti-viral efficacy with an approximately 40% reduction in RSV infection rate and 95% increase in infection-free subjects, represent a key milestone for the advancement of our efforts. These results highlight Alnylam's continued leadership in the field of RNAi therapeutics and our commitment to advancing this promising new class of medicines to patients.





Alnylam is developing an entirely novel class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi. With RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

As scientists continue to decipher the human genome, there has been a remarkable increase in the number of molecular targets associated with a broad range of diseases. The challenge for the industry has been that today's therapeutic modalities – e.g. small molecules and monoclonal antibodies – cannot access most of these disease targets. With RNAi, we can target virtually any gene in the genome involved in the cause or pathway of disease. The implication of targeting previously “undruggable” targets is transformative for new drug discovery.

We have made very significant strides in the development and advancement of RNAi therapeutics. For example, in 2004, Alnylam scientists demonstrated the ability to deliver RNAi therapeutics successfully to achieve the desired therapeutic effect in mice, and in 2006, we achieved similar results in non-human primates; both of these landmark studies were published in the journal *Nature*. In 2008, with our Phase II GEMINI study, we showed for the first time that RNAi works in man when we demonstrated that an RNAi therapeutic achieved statistically significant efficacy in a human clinical trial. By all measures, this represents clear and very rapid progress.

Our strategy at Alnylam is to lead the translation of the science of RNAi into a robust drug discovery capability and to build a significant product pipeline of innovative medicines that we commercialize alone or with partners. Our efforts are well underway in a time when the pace of biomedical discovery is faster than ever and the hunger for innovative medicines is greater than ever. This environment, when combined with our unparalleled intellectual property position for RNAi therapeutics and our industry-leading alliances, creates a unique opportunity for Alnylam to build a leading biopharmaceutical company.



Scientific Leadership

These are exciting times for RNAi therapeutics; important scientific and clinical advancements are being made at a very rapid pace. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the belief that this technology has the potential to make a broad and significant impact in medicine is stronger than ever. Alnylam is leading the effort in translating the science of RNAi into a robust drug discovery capability, with the goal of building a sustainable product pipeline of innovative medicines.

At Alnylam, we are steadfast in our commitment to scientific excellence, and we are driven by our dedication to the highest of scientific standards. A testament to this underlying tenet at Alnylam is the publication of our research in world-leading, peer-reviewed scientific journals, such as *Nature*, *Nature Medicine*, *Nature Biotechnology*, and *Cell*. We believe our numerous publications and collaborations with some of the world's best research labs are important measures of our position as scientific leaders in the field of RNAi. Our scientific papers also serve to demonstrate to leading academic scientists, clinicians, and pharmaceutical executives the potential impact of our discoveries and the opportunity for RNAi to become a new therapeutic approach in medicine.

An important area of scientific focus at Alnylam is developing approaches for the delivery of small interfering RNAs, or siRNAs – the molecules that mediate RNAi – into diseased tissues and cells. Solving the delivery challenge could be one of the most important efforts in all of biomedical research today. Indeed, when researchers can successfully deliver therapeutics to sites of disease, the door is opened for the delivery of RNAi therapeutics to address a broad range of human disease.

Systemic delivery of RNAi therapeutics has been one of the most important challenges in the development of this technology. Although there are a large number of therapeutic areas that can be addressed with direct delivery of an RNAi therapeutic, systemic delivery of these agents enables the broadest potential applications for RNAi therapeutics in the treatment of human disease.

Delivery of siRNAs is one of the most important success factors for the continued advancement of RNAi technology. At Alnylam, we believe that in order to maximize our efforts and success in delivery, we need to develop a “toolkit” of approaches. We have built a very powerful platform around multiple different technologies that have allowed us to successfully deliver our molecules into cells. These approaches include conjugates, antibodies, liposomes, and peptides, to name a few. In fact, we have now achieved gene silencing with our siRNAs directed to more than 25 disease targets, in more than 5 tissues, and in 6 species – including, very recently, humans. Our technology is rapidly emerging as a robust platform that we believe has the potential to rival or even exceed the historical successes of other discovery platforms.





Alnylam

Scientific Leadership

At Alnylam, we have made significant progress in understanding and developing several approaches for the delivery of RNAi therapeutics. In fact, delivery solutions for both direct and systemic administration of siRNAs are now accessible for the clinical advancement of this technology. At the same time, it is our belief that different delivery approaches will be required to access different target tissues, and will require a long-term commitment to continue to expand and evolve this technology over time. Our internal delivery efforts are considerably augmented by the key external partnerships that we formed in 2007, including those with the Massachusetts Institute of Technology (MIT), Tekmira Pharmaceuticals, and Protiva Biotherapeutics, as well as many additional smaller relationships.

The field of microRNAs (miRNAs) is another exciting area of scientific research and Alnylam is playing a major role in translating the emerging science of miRNAs into the therapeutic opportunity they represent. miRNAs are small RNAs that exist naturally within mammalian cells, and these recently discovered genes are believed to regulate the expression of over one-third of all human genes in the genome and have been implicated in cancer, metabolic disease, viral infection, and immune disease.

To better understand and evaluate the opportunity that exists with miRNAs, in 2007 we formed a joint venture with Isis Pharmaceuticals, called Regulus Therapeutics™. We believe the combination of expertise, technology, and know-how from Isis – a leader in the field of antisense therapeutics, and Alnylam – a leader in the field of RNAi therapeutics, positions Regulus Therapeutics to be a leader in the field of miRNA therapeutics. We are very excited about the opportunity that exists for the development of miRNA therapeutics as it may open up a whole new frontier of pharmaceutical research, where entire pathways of disease, not just single disease targets, define the approach for disease intervention.

Regulus Therapeutics LLC is a biopharmaceutical company created to discover, develop, and commercialize miRNA therapeutics. Formed as a joint venture between Alnylam and Isis Pharmaceuticals, Regulus Therapeutics intends to address therapeutic opportunities that arise from abnormal expression or mutations in miRNAs. Because miRNAs regulate the expression of broad networks of genes and biological pathways, miRNA therapeutics define a new strategy to target multiple points in disease pathways. We have assembled world-class scientists and the foremost authorities in the field of miRNA research to lead this new venture. In addition, the joint venture combines the leading capabilities and intellectual property estates of its two parent companies. Thus, in Regulus Therapeutics, we have created the leading miRNA therapeutics company to translate one of the most important new frontiers in modern biology into a new approach for innovative medicines by targeting the pathways of human disease.

Respiratory Syncytial Virus

ALN-RSV01 Respiratory syncytial virus (RSV) is a serious infectious disease and the leading cause of pediatric hospitalizations in the U.S. RSV is also a major infectious disease in the elderly and other adults with compromised immune systems. Alnylam's lead program, ALN-RSV01, is being developed for the treatment of RSV infection.

Since initiating this program in 2005, we have made rapid progress. Our RNAi therapeutic was designed to target the nucleocapsid "N" gene of the RSV genome, a gene that is critical for the replication of the virus. Extensive pre-clinical work in animals demonstrated potent and highly specific anti-viral efficacy with molecular proof of an RNAi mechanism of action. With these promising data, we progressed toward human studies, and our Phase I studies carried out in 2006 and 2007 established the safety and tolerability of ALN-RSV01 in adult human volunteers.


In early 2008, we presented data from our Phase II GEMINI study which showed a statistically significant decrease in infection rate in adults experimentally infected with RSV, demonstrating that ALN-RSV01 has anti-viral activity in a disease setting. With these results, we believe we have demonstrated human proof of concept with an RNAi therapeutic – a first for the field.

We are now preparing to initiate an expanded Phase II program in the naturally infected setting where we aim to further extend our understanding of the safety, tolerability, and anti-viral activity of ALN-RSV01. In early 2008, we initiated a Phase II trial in lung transplant patients and plan to advance ALN-RSV01 into the pediatric patient population later in the year.

We are excited about the progress made with this program, particularly because ALN-RSV01 is a novel therapeutic that has the potential to impact patients infected with RSV in a very significant way. In addition, the anti-viral activity we observed in the GEMINI study increases our confidence as we move toward the naturally infected setting. And perhaps most importantly, we believe the results we have demonstrated to date underscore not only the potential to treat RSV, but the broader potential for RNAi therapeutics in human disease.

RSV is highly contagious and causes infections in both the upper and lower respiratory tracts. RSV typically results in cold-like symptoms but can lead to more serious respiratory illnesses such as croup, bronchiolitis, pneumonia, and in extreme cases, death. RSV infects nearly every child by the age of two and accounts for more than 125,000 hospitalizations annually in the U.S. pediatric population. RSV also poses a great risk to the elderly and to others with compromised immune systems. Recent studies have shown that over 170,000 elderly adults are hospitalized with RSV each year in the U.S., with more than 14,000 deaths in this patient population. There is a clear and significant need for novel therapeutics to treat patients who become infected with RSV.





Alnylam

Product Pipeline

ALN-PCS Hypercholesterolemia, or high levels of cholesterol in the blood, contributes to many diseases, most notably cardiovascular disease – the leading cause of death in the U.S. Alnylam is developing an RNAi therapeutic, ALN-PCS, to treat hypercholesterolemia. ALN-PCS works by silencing a gene called proprotein convertase subtilisin/kexin type 9, or PCSK9, which has been validated as a compelling drug target in human genetics studies. In these studies, individuals with less PCSK9 were found to have lower levels of LDL cholesterol, or bad cholesterol. Because of its novel mechanism of action, we believe that ALN-PCS has the opportunity to treat hypercholesterolemia in a way that current therapies, such as statins, cannot.

In 2007, we advanced ALN-PCS in pre-clinical studies and we have seen promising results, including a greater than 50% reduction in levels of LDL cholesterol in non-human primates. As we advance this program towards a Phase I study in humans, we look forward to demonstrating safety and tolerability in healthy volunteers. In this same early clinical study, we may also have the opportunity to evaluate the efficacy of ALN-PCS in reducing LDL cholesterol levels.

ALN-VSP Liver cancer affects more than one million patients worldwide each year. ALN-VSP is an RNAi therapeutic which we advanced as a development program in 2007, and targets two important genes involved in the disease pathway of liver cancer: kinesin spindle protein, or KSP, and vascular endothelial growth factor, or VEGF. We believe that a dual-target approach in liver cancer increases the potential for a significant therapeutic benefit.

In pre-clinical studies, ALN-VSP demonstrated the ability to silence both KSP and VEGF in the liver and actually stopped the proliferation of cancer cells. In these studies, ALN-VSP showed a striking reduction in the growth and number of significant tumor masses in the liver. We are excited about the potential of this program and the benefit it may provide to liver cancer patients.

ALN-HTT Huntington's disease is an inherited neurodegenerative disease that affects about 30,000 patients in the U.S. today. Alnylam advanced ALN-HTT, an RNAi therapeutic for the treatment of Huntington's disease, as a development program in early 2008. This program is being developed in collaboration with Medtronic, a company which has unmatched expertise in delivering therapeutics directly to the central nervous system, where we aim to develop a drug-device combination product.

In pre-clinical studies, ALN-HTT was well tolerated following administration to the brain and was shown to silence the key gene involved in Huntington's disease. Silencing this gene also translated into a therapeutic effect in animal models, including improvement in motor behavior, which is a hallmark of this debilitating and fatal disease. We look forward to advancing this program, with the hope of eventually providing a treatment approach to a patient population that has no therapeutic options.

The power and potential of RNAi is that it allows for the targeting of virtually any disease-causing gene in the genome. In order to prioritize our efforts, we focus on disease areas with significant unmet medical need, where the biology around the target is well characterized and understood, and where our delivery technologies can achieve efficient and specific effects. Together with our collaborators, we are working towards developing novel therapeutics that have the potential to intervene in the disease processes of these major unmet medical needs.

Overall, 2007 was a transformative year for Alnylam – one in which we achieved major scientific, pipeline, and business milestones. Together, these accomplishments advance our mission of building a leading biopharmaceutical company founded on RNAi. We are more confident than ever in the broad potential of the RNAi opportunity and in our leadership in realizing the technology's promise.

During the course of 2007, our business was greatly strengthened with an increase in alliance and federal funding and sustained leadership on intellectual property (IP). Alnylam continues to operate from a position of financial strength. We ended 2007 with over \$455 million in cash, a financial profile that affords us significant resources to further advance our proprietary and partnered RNAi therapeutic programs as we build our business.



We are proud of our successful track record of executing on key business objectives, and our ability to form landmark collaborations and major alliances is one example of our business leadership. Since our inception in 2002, we have formed more than 40 different relationships with major pharmaceutical companies, other biotechnology companies, the government, and foundations. To date, these relationships have provided us with approximately \$500 million of realized funding. In 2007, these relationships generated over \$50 million in revenue, and we expect they will continue to provide significant future funding in the form of R&D support, milestone payments, and royalties and/or share of profits.

One of our key accomplishments in 2007 was the alliance we formed with Roche, which we believe is the largest drug discovery alliance in the history of biotechnology; it was certainly the largest alliance for the field of RNAi therapeutics and Alnylam's most significant alliance to date. We entered into a non-exclusive license agreement with Roche, providing them access to Alnylam's broad platform IP for the fields of oncology, respiratory disease, metabolic disease, and certain liver diseases. Alnylam received \$331 million in upfront cash and an equity investment from Roche and may also receive significant milestones, royalties, and additional payments to increase the number of therapeutic areas Roche can access, valuing the transaction at over \$1 billion.

Importantly, in the context of this non-exclusive license agreement with Roche, Alnylam is not prohibited from developing any target in any therapeutic area ourselves or with future partners. In addition, we also retain the rights to do similar platform alliances in the future and expect to do so. This includes our partner Novartis, whose pioneering move in RNAi has served them well and where they retain an option to obtain a broad platform license.

Based on leading capabilities in the area of RNAi therapeutics, our track record of execution, and our unparalleled IP estate, we believe we are the collaborator of choice for the development of RNAi therapeutics. Four leading pharmaceutical, biotechnology, and medical device companies have chosen to partner with us, and we also have broad collaborations with leaders in chemistry and delivery technologies. As a testament to the strength of our leading IP estate, we believe more than 50% of all clinical-stage RNAi therapeutics are licensed under Alnylam IP, and more than 75% of sales of RNAi products in the research reagent market are covered under Alnylam IP.





Alnylam

Business Leadership

While our Roche alliance was game-changing for Alnylam, it also enables Roche to build RNAi therapeutics as part of their pipeline for the future. As the largest and broadest partnership for RNAi therapeutics to date, this new alliance also offers continued validation of RNAi as a transformative technology for the discovery of innovative medicines and enables further RNAi discovery and development activities through the efforts of Roche, ultimately advancing the field of RNAi as a whole.

Our success in forming important and major alliances is the result of an active corporate partnering and licensing strategy that leverages our leading scientific and IP positions to build value and grow our business. In fact, aggressively developing our IP estate has been a cornerstone of our business strategy from the early days. We have established what we believe to be an unparalleled IP position and one that we view as necessary for the commercialization of RNAi therapeutics.

Alnylam's IP estate includes fundamental, chemistry, delivery, and target patents. While all of these patents are important, we believe that the fundamental patents define the broadest coverage for the development and commercialization of RNAi therapeutics. There are 11 fundamental patents in the field of RNAi therapeutics issued or granted in the world's major markets; Alnylam is the only company that has access to all 11 and exclusive access to 10 of these patents.

As a result of our leadership positions in business and IP, our confidence remains high in our ability to realize the promise and potential of RNAi therapeutics. To set the stage for the future, we launched our *RNAi 2010* initiative focused on achieving major scientific, clinical, and business milestones by the end of 2010. We believe that execution on our *RNAi 2010* plan will continue to advance RNAi therapeutics as a transformative approach for new medicines and further our mission of building a leading biopharmaceutical company founded on RNAi.

RNAi 2010

Scientific Leadership. By the end of 2010, we expect to broaden our leadership and significantly expand the scope of delivery solutions for RNAi therapeutics. This will be achieved by the continued scientific leadership of Alnylam scientists and current academic and industry collaborators and through a significant external effort to form new delivery technology partnerships. This effort will include the expansion of the range of tissues and cell types where we aim to achieve efficient delivery of RNAi therapeutics with both direct and systemic delivery approaches.

Clinical Pipeline. By the end of 2010, we expect to have four or more RNAi therapeutic programs in clinical development. These will include direct and systemic RNAi programs, Alnylam proprietary and 50/50 partnership programs, and siRNA and miRNA therapeutics.

New Business Collaborations. Based on our scientific, clinical, and IP leadership, we expect to form four or more new major business collaborations by the end of 2010. These are expected to include the completion of additional broad platform alliances, similar to Roche, but also alliances focused on specific RNAi therapeutic programs.

Transformative is how we describe the events of the last year for Alnylam, and for the field of RNAi therapeutics. During this period, we demonstrated human proof of concept for RNAi therapeutics, we completed the biotechnology industry's largest drug discovery alliance in history strengthening our balance sheet with over \$455 million in cash, and we initiated a leading effort to explore an entirely new frontier of pharmaceutical research on miRNA therapeutics. Passion and zeal are how we describe the commitment by Alnylam employees to advance RNAi therapeutics to patients and to continue building a leading biopharmaceutical company in 2008 and beyond.

In last year's letter to our stockholders, I commented on the remarkable times that our industry is experiencing – where the need for meaningful new medicines is greater than ever. Innovation in our industry is increasingly needed for patients, required by regulators, and demanded by payers. While there are risks to this “innovation environment” related to proposed patent reform measures in Congress, the development of high-impact medicines remains the only viable strategy going forward and RNAi therapeutics continue to provide a solution to this challenge. It is for these reasons that RNAi therapeutics – and Alnylam's clear leadership in the field – continue to be highly valued by the broader pharmaceutical industry. Given our progress and this environment, we are more confident than ever in the opportunity before us to build a successful long-term business.

As I reflect on this past year, there are several notable achievements across the dimensions of scientific leadership, pipeline advancement, business execution, and development of our human resources that deserve mention.

Our commitment to scientific excellence remains central to our efforts. We're very proud of our scientists and collaborators, who are making important progress and continue to present Alnylam's leadership in the field of RNAi therapeutics at peer-reviewed meetings and in the world's best scientific journals. Alnylam's research continues to define the pace of new discovery for RNAi therapeutics and represents the standard for the world's efforts in advancing this entire new class of medicines to patients. Delivery remains the most important challenge for the advancement of RNAi therapeutics, and our activities in-house and those with external collaborators continue to advance the broadest opportunities for RNAi therapeutics with systemic delivery solutions. Our commitment to developing novel approaches for the delivery of RNAi therapeutics was cemented in new relationships such as those with Tekmira, Protiva, and the Langer/Anderson lab at MIT.

In 2007, we formalized a new initiative in the emerging area of miRNA therapeutics. Together in a joint venture with Isis, we formed Regulus Therapeutics to focus on this exciting new frontier of pharmaceutical research. Pioneers in miRNA research have joined Regulus Therapeutics as founding Scientific Advisory Board members, including Dr. David Baltimore who is chairing this effort. Regulus Therapeutics is also being led by a high-quality management team.

As mentioned above, a key achievement over the last year was the demonstration of human efficacy for an RNAi therapeutic in our RSV program with ALN-RSV01. The results of our GEMINI study represent a key milestone in the advancement of RNAi therapeutics that now validates our technology with human proof of concept data. While there's more to do, these data greatly

support our overall efforts in advancing this new class of medicines to patients. Over the course of the year, we also made solid progress in our hypercholesterolemia and liver cancer programs and we expect our first systemic RNAi therapeutic investigational new drug (IND) application this year, and extended our pipeline with the advancement of a new development program in Huntington's disease. Our RNAi platform continues to demonstrate the ability to specifically target disease-causing genes, allowing for the creation of a sustainable pipeline of breakthrough medicines. We aim to advance these programs through clinical development toward commercialization in the U.S. market and partner outside of the U.S. to achieve the broadest reach with our novel therapies.

On the business front, we continue to lead the field with an intellectual property (IP) estate for RNAi therapeutics that is simply unmatched in the industry. Today, there are 11 “fundamental” patents issued or granted in the world's major pharmaceutical markets, and Alnylam has access to all these patents and 10 on an exclusive basis. These patents place Alnylam in the strongest possible position to build our company over the long term and will continue to strengthen our efforts as the pharmaceutical industry looks to RNAi as an important strategy for new drug discovery. Of course, a clear proof point for this was our 2007 partnership with Roche: a non-exclusive platform alliance valued at over \$1 billion that included \$331 million in 2007 upfront payments. Our partnership strategy will continue in the future and provides the company with a remarkably strong balance sheet to build a fully integrated biopharmaceutical company.

The success of our company depends on people. Over the recent period we strengthened our Board with the addition of Dr. Ed Scolnick and hired new leadership in our business development, legal, IP, strategy, and human resources functions. We were also pleased to promote Barry Greene into his role as the company's President and Chief Operating Officer. Our new and existing team of scientists and business professionals join me in a commitment to build Alnylam as a leading company.

Finally, at the beginning of 2008, we launched our *RNAi 2010* initiative focused on key achievements in scientific leadership, pipeline development, and business execution through the end of this decade. This initiative is based on our increased confidence in the significance of the broad RNAi opportunity and Alnylam's leadership in realizing its fullest potential. Execution on *RNAi 2010* will continue to advance both RNAi therapeutics as a transformative approach for new medicines and our mission of building a leading biopharmaceutical company founded on RNAi.

In closing, I would like to thank all our stockholders for your interest in Alnylam. We trust that you share in our vision, recognize our passion and zeal in creating a great company that can help patients by impacting disease in a fundamentally new way, and rely on our commitment to harness this revolution in biology.



John M. Maraganore, Ph.D.
 Chief Executive Officer

Corporate Information

Officers and Senior Management

John M. Maraganore, Ph.D.
Chief Executive Officer

Barry E. Greene
President and Chief Operating Officer

Patricia L. Allen
Vice President, Finance and Treasurer

Philip T. Chase
Vice President, Legal

David M. Konys
Vice President, Manufacturing Operations

Victor E. Kotelianski, M.D., Ph.D.
Vice President, Research

Muthiah Manoharan, Ph.D.
Vice President, Drug Discovery

Saraswathy Nochur, Ph.D.
Vice President, Regulatory Affairs

Stuart R. Pollard, Ph.D.
Vice President, Scientific and Business Strategy

Eric W. Raichle
Vice President, Human Resources

Jason P. Rhodes
Vice President, Business Development

Akshay K. Vaishnav, M.D., Ph.D.
Vice President, Clinical Research

Donna T. Ward, Ph.D.
Vice President, Intellectual Property

Board of Directors

John K. Clarke
*Managing General Partner, Cardinal Partners
Chairman of the Board, Alnylam Pharmaceuticals, Inc.*

Victor Dzau, M.D.
*Chancellor for Health Affairs, Duke University
President and CEO, Duke University Health System*

John M. Maraganore, Ph.D.
Chief Executive Officer, Alnylam Pharmaceuticals, Inc.

Vicki L. Sato, Ph.D.
*Professor of Management Practice, Harvard Business School
Professor of the Practice, Department of Molecular and Cell Biology,
Harvard University*

Edward M. Scolnick, M.D.
Director of the Psychiatry Program, Broad Institute

Paul R. Schimmel, Ph.D.
*Ernest and Jean Hahn Professor of Molecular Biology and Chemistry
Skaggs Institute for Chemical Biology, The Scripps Research Institute*

Phillip A. Sharp, Ph.D.
*Institute Professor, Massachusetts Institute of Technology
Nobel Laureate in Physiology or Medicine, 1993*

Kevin P. Starr
Partner, Third Rock Ventures

James L. Vincent, Ph.D.
Former Chairman and CEO of Biogen, Inc. (now Biogen Idec Inc.)

Stockholder Information**Corporate Headquarters**

Alnylam Pharmaceuticals, Inc.
300 Third Street
Cambridge, Massachusetts 02142
617.551.8200

Independent Auditors

PricewaterhouseCoopers LLP, Boston, Massachusetts

Transfer Agent and Registrar

Questions regarding accounts, address changes, stock transfers and lost certificates should be directed to:

Computershare Trust Company, N.A.
P.O. Box 43078
Providence, Rhode Island 02940-3078
Shareholder Inquiries 781.575.2879
www.computershare.com

Annual Meeting

The 2008 Annual Meeting of Stockholders will be held on June 3, 2008 at 9:00 a.m. at the offices of Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, Massachusetts 02142.

Price Range of Common Stock

The following table sets forth the high and low sales prices per share for our common stock on the NASDAQ National Market for the periods indicated.

	2007		2006	
	High	Low	High	Low
First Quarter	\$22.94	\$16.66	\$18.39	\$11.48
Second Quarter	20.68	15.06	17.63	12.82
Third Quarter	34.85	14.87	15.52	11.29
Fourth Quarter	37.35	26.84	24.46	13.77

We have never paid or declared any cash dividends on our common stock. We currently intend to retain any earnings for future growth and, therefore do not expect to pay cash dividends in the foreseeable future.

This document contains forward-looking statements that involve risks and uncertainties. Any statements (including statements to the effect that we "believe" and similar expressions) that are not statements relating to historical matters should be considered forward-looking statements. Actual results may differ materially from those discussed in the forward-looking statements as a result of numerous important factors, including those discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the Securities and Exchange Commission, a copy of which is included herein.



Alynam Pharmaceuticals, Inc.
300 Third Street · Cambridge, MA 02142 · 617 551 8200 · www.alnylam.com

© 2008 Alynam Pharmaceuticals, Inc. All rights reserved. Regulus Therapeutics™ is a trademark of Regulus Therapeutics LLC. Alynam BioDefense™ is a trademark of Alynam Pharmaceuticals, Inc. Alynam® and Harnessing a revolution in biology for human health® are registered trademarks of Alynam Pharmaceuticals, Inc.